InnoCan Pharma (TSE:INNO) has released an update.
Innocan Pharma is shifting its focus towards its Liposome Platform Technology-Cannabidiol (LPT-CBD) after receiving encouraging progress from the FDA, targeting the booming veterinary market. With the U.S. pet industry projected to reach $156 billion in 2024, Innocan aims to capture the growing demand for effective chronic pain treatments for animals. The company has decided to conclude its Cannabinoid-Loaded Exosome (CLX) project to better allocate resources towards the promising LPT-CBD platform.
For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.
